GlassScriptPhysician profile
Howard Michael Braver
NPI 1184672123
$12,352.88
in general payments reported to CMS, 2019-2025
64 companies · $1,648 in 2025
The $1,648 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,553 · 2020: $1,778 · 2021: $1,919 · 2022: $1,640 · 2023: $1,684 · 2024: $1,131 · 2025: $1,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,463.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,825.49 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,766.60 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,151.21 | 2019-2025 | Jascayd, Spiriva, Jardiance |
| Mallinckrodt Hospital Products INC. | $799.38 | 2020-2023 | Acthar |
| Mylan Specialty L.P. | $624.97 | 2019-2024 | Yupelri |
| Pfizer INC. | $606.69 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $555.99 | 2022-2025 | Purified Cortrophin Gel |
| Insmed, INC. | $519.06 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $449.26 | 2021-2025 | |
| Mallinckrodt Enterprises LLC | $401.84 | 2019 | |
| Abbvie INC. | $228.32 | 2021-2023 | Ubrelvy, Qulipta, Linzess |
| Novo Nordisk INC | $211.30 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $170.35 | 2019-2022 | |
| Abbott Laboratories | $167.22 | 2019 | |
| Amgen INC. | $165.40 | 2019-2024 | Otezla, Repatha |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Braver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.